BMS-354825

BMS-354825 information and resources from the National Cancer Institute

NCI Thesaurus | BMS-354825

An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. BMS-354825 binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, BMS-354825 has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.NCI Thesaurus | BMS-354825

An orally bioavailable synthetic small molecule-inhibitor of SRC-family protein-tyrosine kinases. BMS-354825 binds to and inhibits the growth-promoting activities of these kinases. Apparently because of its less stringent binding affinity for the BCR-ABL kinase, BMS-354825 has been shown to overcome the resistance to imatinib of chronic myeloid leukemia (CML) cells harboring BCR-ABL kinase domain point mutations. SRC-family protein-tyrosine kinases interact with variety of cell-surface receptors and participate in intracellular signal transduction pathways; tumorigenic forms can occur through altered regulation or expression of the endogenous protein and by way of virally-encoded kinase genes.

Novartis May Pay SGX More Than $515 Million in Accord (Update3) Mar 28, 2006
Bloomberg Data presented in December 2004 suggested that about 86 percent of Gleevec-resistant patients responded to Bristol- Myers's BMS-354825 in a small safety study. ...

SGX, Novartis Sign $515M Deal Mar 28, 2006
Red Herring, However, Bristol may introduce its drug in the middle of this year, and about 86 percent of Gleevec-resistant patients responded to the drug BMS-354825 in a ...

Inhibition of Src Expression and Activity Inhibits Tumor ... Feb 28, 2006
Am J Pathology (subscription) To examine this possibility further, animals bearing established wild-type tumors were treated with the Src/Abl-selective inhibitor BMS-354825 (dasatinib). ...

BMS-354825 -->